Login to Your Account



Sublicensing Right to UCB, $30M to Immunomedics

Immunomedics, UCB Rework Agreement for Lupus Drug

By Marie Powers
Staff Writer

Wednesday, January 4, 2012
Immunomedics Inc. and development partner UCB SA revised their development, collaboration and license agreement for the exclusive worldwide rights to develop, market and sell Immunomedics' epratuzumab for autoimmune disease indications.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription